ASCO - Multiple Myeloma Research Foundation

LIVE FROM ASC0 2016 : June 3 - June 7 : Chicago, Illinois


MMRF Holds CoMMpass Collaborator Meetings at ASCO 2016

On Saturday June 4 at ASCO, the MMRF Research Team met with our CoMMpass trial collaborators to discuss the current status of the trial and new directions for CoMMpass in the near future. Read More

June 20, 2016

ASCO Educational Session: Consolidation and Maintenance: Moving Beyond Autotransplant

The learning objectives for this session included: 1. Describing optimal approaches and evidence-based data outlining the role of consolidation therapy after autologous transplant. 2. Discussing when and how to choose maintenance approaches, including the duration of therapy. 3. Identifying which patients are best suited for an allogeneic transplant approach, and current clinical trials that are making successful headway. Read More

June 9, 2016

Day Three Wrap-Up: ASCO 2016

Last year daratumumab (Darzalex) received accelerated approval by the U.S. Food and Drug Administration to treat myeloma patients that had at least three prior therapies. Daratumumab was the first human monoclonal antibody to be approved for the treatment of myeloma. Read More

June 7, 2016

Day Two Sessions: ASCO 2016

The MMRF/MMRC team is spending nearly a week at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting and we are pleased to share with you some key highlights from the multiple myeloma (MM) data presented. The oral session this morning attracted a large crowd of attendees, so there was much anticipation for the data! Read More

June 4, 2016

Day One: ASCO 2016

American Society of Clinical Oncology (ASCO) 2016, the largest international meeting focused specifically on oncology, opened yesterday. Late in the afternoon, the first presentations focused on multiple myeloma (MM) were given. Topics ranged from research centered around better defining and identifying patients with smoldering multiple myeloma (SMM) that is likely to progress toward active MM (i.e. that requires treatment), treatments for patients with newly diagnosed MM to novel treatments and combinations for relapsed and refractory MM. Read More

June 4, 2016